September 20, 2001

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

.   .   

A landmark randomized controlled trial which showed that, compared to placebo, losartan reduced the incidence of a doubling of the serum creatinine concentration and end-stage renal disease.

Related Articles:

Chronic Kidney Disease, Diabetes, RAS Blockade

Comments are closed.